Osteosarcoma incidence did not increase with teriparatide use
During a 15‐year surveillance period, no difference in the incidence of osteosarcoma was associated with teriparatide use, according to a study.
Researchers used a standardized incidence ratio to estimate and compare the observed and expected numbers of osteosarcoma patients with a prior history of teriparatide use.
Of the 1,173 patients diagnosed with osteosarcoma between 2003 and 2016 included in this study, 3 reported using teriparatide before osteosarcoma diagnosis. The background incidence rate expected there to be 4.17 patients treated with teriparatide in the osteosarcoma cases. the standardized incidence ratio was 0.72 (90% confidence interval, 0.20‐1.86).
Risk factors for development of osteosarcoma among the osteosarcoma cohort were history of radiation (19%) and history of Paget’s disease of bone (4%).
Teriparatide did not increase adult osteosarcoma incidence in a 15‐Year US postmarketing surveillance study. JBMR. 2020; https://doi.org/10.1002/jbmr.4188